E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
LPS induced acute inflammatory state in healthy volunteers |
|
E.1.1.1 | Medical condition in easily understood language |
LPS infusion leads to an acute, transient inflammatory state in otherwise healthy volunteers |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate whether vorapaxar reduces LPS induced coagulation activation assessed by prothrombin fragments F1+2 |
|
E.2.2 | Secondary objectives of the trial |
to investigate whether vorapaxar reduces LPS induced: - coagulation activation and fibrinolysis (TAT, DDimer, PAP, etc.) - platelet activation and aggregation (PF4, Whole blood aggregometry, Verify now, etc.) - endothelial activation (vWF activity, endothelial glycocalyx thickness etc.) - cell counts and subsets of monocytes effects of endotoxemia on: platelet proteasome, neutrophil patterns (facs), platelet activation and LPS washout effects
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• ≥18 years of age • ≥60 kg bodyweight • Normal findings in medical history and physical examination unless the investigator considers the abnormality to be clinically irrelevant • Normal laboratory values unless the investigator considers abnormalities to be clinically irrelevant • Willingness to comply with the trial’s safety demands (to refrain from excessive sporting activities two weeks after Vorapaxar intake, i.e. full contact sports, climbing, mountain biking etc.) • Ability to understand the purpose and nature of the study, as well as the associated risks • No planned surgeries or other medical interventions in the planned study period
|
|
E.4 | Principal exclusion criteria |
• Intake of any drugs that may interfere with the trial’s endpoints or drugs (i.e. platelet inhibitors, anticoagulants, CYP3A4 inhibitors, NSAIDs, SSRI, SNRI) • Positive results of HIV or hepatitis virology • Acute illness with systemic inflammatory reactions • Known allergies, hypersensitivities or intolerances to any of the used substances • Acute or recent bleeding episodes, increased risk of bleeding at the discretion of the investigator • History of stroke, transient ischemic attacks or intracerebral hemorrhage • Known coagulation or platelet disorders • Participation in an LPS trial within 6 weeks of the first study day • Severe liver or kidney dysfunction
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
prothrombin fragments F1+2 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
repeated measures between two study periods (placebo vs. vorapaxar, crossover study) two to four hours after lps bolus usually highest values of prothrombin fragments F1+2 are measured. Thus, main effects will be measured at that time point. |
|
E.5.2 | Secondary end point(s) |
-coagulation activation and fibrinolysis (TAT, PAP, tpa, thrombelastometry etc.) - platelet activation and aggregation (PF4, Whole blood aggregometry, Verify now, proteasome etc.) - inflammation and endothelial activation (endothelial glycocalyx, vWF, etc., TSP-1) - cell counts and monocyte/neutrophil subsets |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
-24h as baseline 0h before LPS, but 24h after vorapaxar 1h 1,5h 2h 4h 6h 8h 24h after LPS infusion |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last follow up visit of last participant |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |